• Green Tea Epigallocatechin Gallate Enhances In Vitro Immunomodulatory and Beta Cell Protective Functions in Streptozotocin-Induced Diabetic Mice Model with Bone-marrow-Derived Mesenchymal Stem Cells
  • Fatemeh Ahmadzadeh,1 Saeid AbedianKenari,2,*
    1. Immunogenetics Research center, Department of immunology, Faculty of Medicine,Mazandaran university of medical sciences, sari, Mazandaran, IRAN
    2. Immunogenetics Research center, Department of immunology, Faculty of Medicine,Mazandaran university of medical sciences, sari, Mazandaran, IRAN


  • Introduction: Mesenchymal stem cells (MSC) are judged by their ability as an immunomodulator and their potential to regenerate the insulin secreting cells in type 1 diabetes (T1D). However, some experimental results indicate that the high glucose concentration or diabetic environment suppresses some crucial proteins and increases senescence in stem cells. Regarding antioxidative and immunosuppression characteristics of epigallocatechin-3-gallate (EGCG), the present study investigated the feasibility of using EGCG, along with MSCs, to improve regeneration in pancreatic beta cell line (bTC3) and modulation in immune responses.
  • Methods: MSCs were extracted from bone marrow of normal mice and cultured. Diabetes was induced in the mice by administration of multiple low-doses of streptozotocin. Splenocytes were prepared from normal and diabetic mice. Proliferation, cytokine production and insulin secretion assays were performed in coculture experiments.
  • Results: Comparing with other groups, significant improvement in viability as well as insulin secretion of treated bTC3 cells was observed in the MSC+ EGCG group. The EGCG and MSCs treatment more efficiently inhibited splenocyte proliferative response to trigger. Decreased production of IFN-Ɣ as a proinflammatory cytokine and increased secretion of IL-4 as a regulatory cytokine by stimulated splenocytes were also shown in response to stimulant.
  • Conclusion: On the whole, it seems that natural anti-inflammatory products and stem cell treatment cross-effect may provide a new horizon for T1D cell therapy and islet transplantation in the future.
  • Keywords: Mesenchymal Stem Cell, Epigallocatechin gallate, Type 1 diabetes